The past, present and future of renin-angiotensin aldosterone system inhibition

被引：92

作者：

Mentz, Robert J. ^{[1
]}

Bakris, George L. ^{[2
]}

Waeber, Bernard ^{[3
,4
]}

McMurray, John J. V. ^{[5
]}

Gheorghiade, Mihai ^{[6
]}

Ruilope, Luis M. ^{[7
]}

Maggioni, Aldo P. ^{[8
]}

Swedberg, Karl ^{[9
]}

Pina, Ileana L. ^{[10
]}

Fiuzat, Mona ^{[1
]}

O'Connor, Christopher M. ^{[1
]}

Zannad, Faiez ^{[11
]}

Pitt, Bertram ^{[12
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27710 USA

[2] Univ Chicago Med, Chicago, IL USA

[3] CHU Vaudois, Lausanne, Switzerland

[4] Univ Lausanne, Lausanne, Switzerland

[5] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland

[6] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA

[7] Hosp 12 Octubre, E-28041 Madrid, Spain

[8] Assoc Nazl Med Cardiol Osped Res Ctr, Florence, Italy

[9] Univ Gothenburg, Gothenburg, Sweden

[10] Montefiore Einstein Med Ctr, New York, NY USA

[11] Ctr Invest Clin, Nancy, France

[12] Univ Michigan, Sch Med, Univ Hosp, Ann Arbor, MI USA

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2013年 / 167卷 / 05期

关键词：

Renin-angiotensin aldosterone system; Hypertension; Heart failure; Myocardial infarction; Clinical trials; CONVERTING-ENZYME-INHIBITORS; CHRONIC HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; MINERALOCORTICOID RECEPTOR ACTIVATION; HIGH-RISK PATIENTS; ATRIAL-FIBRILLATION; DOUBLE-BLIND; RANDOMIZED-TRIAL; II-RECEPTOR;

D O I：

10.1016/j.ijcard.2012.10.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1677 / 1687

页数：11

共 129 条

[1] Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism [J].

Amar, Laurence ;

Azizi, Michel ;

Menard, Joel ;

Peyrard, Severine ;

Watson, Catherine ;

Plouin, Pierre-Francois .

HYPERTENSION, 2010, 56 (05) :831-+

[2] THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].

AMBROSIONI, E ;

BORGHI, C ;

MAGNANI, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85

[3] 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [J].

Anderson, Jeffrey L. ;

Adams, Cynthia D. ;

Antman, Elliott M. ;

Bridges, Charles R. ;

Califf, Robert M. ;

Casey, Donald E., Jr. ;

Chavey, William E. ;

Fesmire, Francis M. ;

Hochman, Judith S. ;

Levin, Thomas N. ;

Lincoff, A. Michael ;

Peterson, Eric D. ;

Theroux, Pierre ;

Wenger, Nanette Kass ;

Wright, R. Scott ;

Anderson, Jeffrey L. ;

Adams, Cynthia D. ;

Bridges, Charles R. ;

Casey, Donald E., Jr. ;

Ettinger, Steven M. ;

Fesmire, Francis M. ;

Ganiats, Theodore G. ;

Jneid, Hani ;

Lincoff, A. Michael ;

Peterson, Eric D. ;

Philippides, George J. ;

Theroux, Pierre ;

Wenger, Nanette K. ;

Zidar, James Patrick ;

Jacobs, Alice K. ;

Anderson, Jeffrey L. ;

Albert, Nancy ;

Hochman, Judith S. ;

Creager, Mark A. ;

Kushner, Frederick G. ;

Ettinger, Steven M. ;

Ohman, Erik Magnus ;

Guyton, Robert A. ;

Stevenson, William G. ;

Halperin, Jonathan L. ;

Yancy, Clyde W. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (19) :E215-E367

[4]

[Anonymous], LANCET

[5]

Antihypertensive T., 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama.288.23.2981, DOI 10.1001/JAMA.288.23.2981]

[6]

Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI [10.1016/j.jacc.2008.04.002, 10.1016/j.jacc.2007.10.001]

[7] The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure [J].

Bakris, George L. ;

Sica, Domenic ;

Weber, Michael ;

White, William B. ;

Roberts, Andrew ;

Perez, Alfonso ;

Cao, Charlie ;

Kupfer, Stuart .

JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (02) :81-88

[8]

BALL SG, 1993, LANCET, V342, P821

[9] The Role of Angiotensin Receptor Blockers in Patients with Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema [J].

Beavers, Craig James ;

Dunn, Steven P. ;

Macaulay, Tracy E. .

ANNALS OF PHARMACOTHERAPY, 2011, 45 (04) :520-524

[10] Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease [J].

Bertocchio, Jean-Philippe ;

Warnock, David G. ;

Jaisser, Frederic .

KIDNEY INTERNATIONAL, 2011, 79 (10) :1051-1060

← 1 2 3 4 5 6 7 8 9 10 →